**Drug Therapy Protocols: Methoxyflurane**

**Disclaimer and copyright**
©2018 Queensland Government

All rights reserved. Without limiting the reservation of copyright, no person shall reproduce, store in a retrieval system or transmit in any form, or by any means, part or the whole of the Queensland Ambulance Service (‘QAS’) Clinical practice manual (‘CPM’) without the prior written permission of the Commissioner.

The QAS accepts no responsibility for any modification, redistribution or use of the CPM or any part thereof. The CPM is expressly intended for use by QAS paramedics when performing duties and delivering ambulance services for, and on behalf of, the QAS.

Under no circumstances will the QAS, its employees or agents, be liable for any loss, injury, claim, liability or damages of any kind resulting from the unauthorised use of, or reliance upon the CPM or its contents.

While effort has been made to contact all copyright owners this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome, please forward to: Clinical.Guidelines@ambulance.qld.gov.au

<table>
<thead>
<tr>
<th>Date</th>
<th>April, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purpose</strong></td>
<td>To ensure a consistent procedural approach to Methoxyflurane administration.</td>
</tr>
<tr>
<td><strong>Scope</strong></td>
<td>Applies to all QAS clinical staff.</td>
</tr>
<tr>
<td><strong>Author</strong></td>
<td>Clinical Quality &amp; Patient Safety Unit, QAS</td>
</tr>
<tr>
<td><strong>Review date</strong></td>
<td>April, 2021</td>
</tr>
<tr>
<td><strong>Information security</strong></td>
<td>This document has been security classified using the Queensland Government Information Security Classification Framework (QGISCF) as UNCLASSIFIED and will be managed according to the requirements of the QGISF.</td>
</tr>
</tbody>
</table>

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Methoxyflurane

Drug class
Analgesic (at low doses)

Pharmacology
Methoxyflurane is volatile, self-administered inhalation analgesic indicated for short-term pain relief. Methoxyflurane is more susceptible to metabolism than other halogenated ethers and has a greater propensity to diffuse into fatty tissue.[1-3]

Metabolism
By the liver and excreted mainly by the lungs.[3]

Indications
• Pain

Contraindications
• Allergy and/or Adverse Drug Reaction
• Patients < 1 year
• History of significant liver or renal disease
• History of malignant hyperthermia

Precautions
• ALOC
• Intoxicated or drug affected patients

Side effects
• ALOC
• Cough
• Renal/hepatic failure (following repeated high dose exposure)

Presentation
• Bottle, 3 mL methoxyflurane

Onset (INH) | Duration (INH) | Half-life
--- | --- | ---
1–3 minutes | 5–10 minutes | Not available

April, 2018
Special notes

• Experimental and clinical use of methoxyflurane in the low dose used for analgesia does not carry any particular risk of causing renal dysfunction or damage.[3]

• The manufacturer recommends the use by children only when they self-monitor pain and self-administer methoxyflurane with the inhaler. Poor administration will lead to ineffective analgesia.

• Deep sedation has been identified with methoxyflurane administration in patients < 5 years.[1,4]

• At no time should unconsciousness be deliberately induced using methoxyflurane.

• At no time should a patient self-administering methoxyflurane be left unattended.

• The lowest dose of methoxyflurane to provide analgesia should be used.[1]

• If the patient prefers simultaneous inhalation through both nose and mouth, the inhaler may be connected into a standard anaesthetic face mask prior to administration.[2]

Special notes (cont.)

• The total weekly dose should not exceed 15 mL with administration on consecutive days not recommended.[4]

• To reduce the risk of occupational exposure to methoxyflurane, officers are to ensure the following:
  - Only one dose of 3 mL should be administered per patient whilst in the ambulance vehicle.
  - No single officer should administer more than two doses of methoxyflurane in the ambulance vehicle per shift.
  - Where possible, ambulance vehicles are to be adequately ventilated.

Adult dosages

<table>
<thead>
<tr>
<th>Pain</th>
<th>INH</th>
<th>3 mL</th>
<th>Repeated once after 20 minutes. Total maximum dose 6 mL.</th>
</tr>
</thead>
</table>

Paediatric dosages

<table>
<thead>
<tr>
<th>Pain</th>
<th>INH</th>
<th>≥ 1 year – 3 mL Single dose only.</th>
</tr>
</thead>
</table>
Methoxyflurane Preparation / Administration Instruction

1. Tilt the PENTHROX® inhaler to a 45° angle and pour the contents of one 3 mL bottle into the base whilst rotating.

2. Instruct the patient to inhale and exhale gently through the mouthpiece.

3. If stronger analgesia is required, the patient may be instructed to temporarily cover the dilution hole with their own finger to increase concentration.